Pacific Biosciences of California, Inc. (PACB) Social Stream
Featured Post From StockTwits About PACB
$PACB $BNGO Great example of the two technologies are used together in by a Pathology doctor:PotentCatalyst, published June 20, 2021
The doctor first used Bionano to see SV(repeat expansion) and Somatic mosaicism
Then the doctor want to see what is the composition of repeat sequence, and used Pacbio to sequence it
Find out Pacbio and Bionano is comparable in detecting repeat length and somatic mosaicism, but only Pacbio can determine the genomic repeat structure
End up the entire patient family, 13 patients were studied using Pacbio but only 4 was studied using Bionano
What Else are PACB Traders Talking About?
Other tickers frequently mentioned alongside PACB is BNGO.
Other Notable StockTweets About PACB
$PACB Not looking good. @Guest99 sent this to me. 900m from softbank might not be enough money.
So How Risky Is Pacific Biosciences of California?
We have no doubt that loss making companies are, in general, riskier than profitable ones. And in the last year Pacific Biosciences of California had an earnings before interest and tax (EBIT) loss, truth be told. And over the same period it saw negative free cash outflow of US$80m and booked a US$59m accounting loss. Given it only has net cash of US$264.6m, the company may need to raise more capital if it doesn't reach break-even soon.
$BNGO Total revenue was $3.2 million for the three months ended March 31, 2021, up 179% from $1.1 million in the same period of 2020. If you go to “ARK’s Big Ideas 2021” presentation on slide 93 you will see BNGO is talked about on there along with $PACB. Our Discord contains in-depth due diligence on this company and will continue to monitor price action with technical analysis! IG: @thedangmedia
FREE DISCORD LINK: https://discord.com/invite/AGUVQA5hcn
OMG! ARK Invest thinks BNGO technology will be obsolete soon! This will further reduce the revenue of BNGO. Reason why ARK did not invest in this company!
"long-read sequencing ($PACB) is sufficient to map 100% of the human genome with base-level accuracy higher than short-reads."